These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 24839602)
1. The emerging role of biotechnological drugs in the treatment of gout. Cavagna L; Taylor WJ Biomed Res Int; 2014; 2014():264859. PubMed ID: 24839602 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic perspectives on uricases for gout. Garay RP; El-Gewely MR; Labaune JP; Richette P Joint Bone Spine; 2012 May; 79(3):237-42. PubMed ID: 22366146 [TBL] [Abstract][Full Text] [Related]
5. [Gout: an overview of available urate lowering therapies]. Richette P Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581 [TBL] [Abstract][Full Text] [Related]
7. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. Biggers K; Scheinfeld N Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109 [TBL] [Abstract][Full Text] [Related]
8. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Mandell BF; Yeo AE; Lipsky PE Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229 [TBL] [Abstract][Full Text] [Related]
9. Reversal of chronic refractory tophaceous gout with erosions with pegloticase. Yeter KC; Ortiz EC; Arkfeld DG Int J Rheum Dis; 2013 Jun; 16(3):369-70. PubMed ID: 23981765 [No Abstract] [Full Text] [Related]
10. Pegloticase and the patient with treatment-failure gout. Dave AJ; Kelly VM; Krishnan E Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270 [TBL] [Abstract][Full Text] [Related]
11. Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide? Fini MA; Stenmark KR Eur J Intern Med; 2019 Nov; 69():e11-e12. PubMed ID: 31471165 [No Abstract] [Full Text] [Related]
12. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy. Dalbeth N; Doyle AJ; McQueen FM; Sundy J; Baraf HS Arthritis Care Res (Hoboken); 2014 Jan; 66(1):82-5. PubMed ID: 23836458 [TBL] [Abstract][Full Text] [Related]
13. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout. Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591 [TBL] [Abstract][Full Text] [Related]
14. Evaluation and treatment of gout as a chronic disease. Perez-Ruiz F; Herrero-Beites AM Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464 [TBL] [Abstract][Full Text] [Related]
15. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Schlesinger N; Lipsky PE Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200 [TBL] [Abstract][Full Text] [Related]
16. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. Johnson RJ; Choi HK; Yeo AE; Lipsky PE Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535 [TBL] [Abstract][Full Text] [Related]
17. New therapies for gout. Crittenden DB; Pillinger MH Annu Rev Med; 2013; 64():325-37. PubMed ID: 23327525 [TBL] [Abstract][Full Text] [Related]
18. Development of a multivariable improvement measure for gout. Schlesinger N; Edwards NL; Yeo AE; Lipsky PE Arthritis Res Ther; 2020 Jun; 22(1):164. PubMed ID: 32600452 [TBL] [Abstract][Full Text] [Related]